GSA Capital Partners’s Monte Rosa Therapeutics GLUE Stock Holding History

GSA Capital Partners’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,981	Closed	-$204K	–	1895
2025 Q4	$204K	Sell	12,981 -120,474	-90%	-$1.62M	0.02%	1402
2025 Q3	$989K	Sell	133,455 -150,357	-53%	-$796K	0.08%	405
2025 Q2	$1.28M	Buy	283,812 +268,650	+1,772%	+$1.2M	0.09%	318
2025 Q1	$70K	Buy	+15,162	New	+$93K	0.01%	1533
2024 Q3	–	Sell	-25,346	Closed	-$95K	–	1757
2024 Q2	$95K	Buy	+25,346	New	+$129K	0.01%	1531
2022 Q4	–	Sell	-19,084	Closed	-$156K	–	1624
2022 Q3	$156K	Buy	+19,084	New	+$175K	0.02%	1286

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

GSA Capital Partners's GLUE Position: Q1 2026 in Review

GSA Capital Partners sold out of Monte Rosa Therapeutics (GLUE) in Q1 2026, closing a stake of 12,981 shares — an estimated $204K sold.

GSA Capital Partners first reported a position in GLUE in Q3 2022 and held it in 6 quarters. The position peaked at $1.28M in Q2 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

GSA Capital Partners reported no remaining Monte Rosa Therapeutics position as of Q1 2026 after selling out during the quarter.
GSA Capital Partners sold 12,981 Monte Rosa Therapeutics shares in Q1 2026, an estimated $204K.
GSA Capital Partners first reported a position in Monte Rosa Therapeutics in Q3 2022 and held it in 6 quarters.
GSA Capital Partners's Monte Rosa Therapeutics position peaked at $1.28M in Q2 2025.
190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.